Lupin Ltd.


  • 1m
  • 3m
  • 6m
  • 1y
  • 2y
  • 5y
Apr 21, 2017
Prev close: 1,409.1
Apr 21, 2017
Market cap:
Market cap(USD):
Shares: 451.57M

Currency in INR

Company profile

Market(Ticker): BOM(500257)
Health Technology
Pharmaceuticals: Generic
Full time employees: 20,587

Business summary

Lupin Ltd. operates as a pharmaceuticals company, which manufactures and distributes pharmaceutical ingredients and formulations. It offers products in growth therapy segments, such as cardiology, central nervous system, anti-diabetic, anti-TB, anti-asthma, gynaecology, anti-infective, gastro-intestinal and others. Lupin was founded by Desh Bandhu Gupta in 1968 and is headquartered in Mumbai, India.

Company background

Lupin is a major generic drugmaker that conducts business in more than 100 countries. Among India's five biggest pharmaceuticals, it has about 10 production bases in India and exports generic drugs to other countries.

It was founded in 1968 by Desh Bandhu Gupta, a researcher at a science university. Since the early 2000s, it has been actively buying companies in South Africa, Mexico, even Japan.

It got a head start on its Indian competitors by building a supply network in Japan. It did so in 2007 by acquiring Kyowa Pharmaceutical Industry, an Osaka-based medium-size generic drugmaker. In 2014, it set up a venture with Yoshindo, a generic drug company based in Japan's Toyama Prefecture, to jointly develop generic biomedicines.

Zyma Laboratories, an affiliate company run by Desh Bandhu Gupta and other executives, is Lupin's top shareholder; the founding family still owns some shares in Lupin.

In the news

Financial highlights

Mar 2016

  • Local currency
  • US Dollar
Revenue 137,084.2M
Gross profit 66,570.2M
Operating income 28,425.8M
Income before tax 34,330.3M
Net income 22,706.9M
EBITDA 33,060.8M
Diluted EPS 50.15
Dividends per share 7.5
Total assets 225,575.4M
Total liabilities 115,410.9M
Total equity 109,834.5M
Operating cash flow -3,661.7M

Currency in INR

Revenue 2,093.82M
Gross profit 1,016.79M
Operating income 434.17M
Income before tax 524.36M
Net income 346.82M
EBITDA 504.96M
Diluted EPS 0.76
Dividends per share 0.11
Total assets 3,406.32M
Total liabilities 1,742.77M
Total equity 1,658.56M
Operating cash flow -55.92M

Currency in USD

Valuation measures

Mar 2016

PER 29.34
ROA 12.69%
ROE 22.87%
Operating margin 20.73%
Profit margin 16.56%

Key executive

  • Managing Director & Executive Director: Nilesh Deshbandhu Gupta
  • Chief Executive Officer & Executive Director: Vinita Gupta Sharma
  • Chief Financial Officer & Executive Director: Ramesh Swaminathan
  • Secretary & Compliance Officer: Rajvardhan V. Satam
  • Group President-India Region Formulations & CIS: Shakti Chakraborty

Share holders

  • Zyma Laboratories Ltd.(12.3%)
  • Rahas Investments Ltd.(10.2%)
  • Visiomed Investments Pvt. Ltd.(9.7%)
  • Lupin Holdings Pvt. Ltd.(9.0%)
  • Lupin Investments Pvt Ltd.(3.4%)
  • First State Investment Management (UK) Ltd.(2.6%)
  • Genesis Investment Management LLP(2.1%)
  • The Vanguard Group, Inc.(1.5%)
  • GIC Pte Ltd. (Investment Management)(1.4%)


  • Website:
  • Address: B/4 Laxmi Towers, Bandra (East), Mumbai, 400051, India
  • Phone: +91.22.66402222

Copyright © 2017 FactSet Research Systems Inc. All rights reserved.